CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock	Treasury Shares	Paid-In Capital	Accumulated Other Comprehensive Income	Retained Earnings
Beginning balance (in shares) at Dec. 31, 2020		478,000,000
Beginning balance (in shares) at Dec. 31, 2020			79,000,000
Balance at beginning of period at Dec. 31, 2020	$ 2,216	$ 48	$ (1,823)	$ 1,804	$ 2	$ 2,185
Increase (Decrease) in Stockholders' Equity
Net income	1,158
Issuance of common stock for merger (in shares)		408,000,000
Issuance of common stock for merger	9,083	$ 41		9,042
Issuance of replacement awards and options for merger consideration (in shares)		4,000,000
Issuance of replacement awards and options for merger consideration	37			37
Exercise of stock options	2			2
Stock amortization and vesting (in shares)		3,000,000
Stock amortization and vesting	23		$ (3)	26
Common stock retirements	0
Common stock cash dividends	(779)					(779)
Preferred stock cash dividends	(1)					(1)
Other comprehensive (loss) income	(1)				(1)
Ending balance (in shares) at Dec. 31, 2021		893,000,000
Ending balance (in shares) at Dec. 31, 2021			79,000,000
Balance at end of period at Dec. 31, 2021	11,738	$ 89	$ (1,826)	10,911	1	2,563
Increase (Decrease) in Stockholders' Equity
Net income	4,065					4,065
Exercise of stock options (in shares)		1,000,000
Exercise of stock options	12			12
Stock amortization and vesting (in shares)		1,000,000	1,000,000
Stock amortization and vesting	46	$ 1	$ (9)	54
Common stock repurchases (in shares)			48,000,000
Common stock repurchases	(1,250)		$ (1,250)
Common stock retirements (in shares)		(128,000,000)	(128,000,000)
Common stock retirements	(3,085)	$ (13)	$ 3,085	(3,072)
Conversion of Cimarex redeemable preferred stock (in shares)		1,000,000
Conversion of Cimarex redeemable preferred stock	28			28
Common stock cash dividends	(1,991)					(1,991)
Preferred stock cash dividends	(1)					(1)
Other comprehensive (loss) income	$ 12				12
Ending balance (in shares) at Dec. 31, 2022		768,000,000
Ending balance (in shares) at Dec. 31, 2022	0		0
Balance at end of period at Dec. 31, 2022	$ 12,659	$ 77	$ 0	7,933	13	4,636
Increase (Decrease) in Stockholders' Equity
Net income	$ 1,625					1,625
Exercise of stock options (in shares)	113,500
Exercise of stock options	$ 2			2
Stock amortization and vesting	56		$ (9)	65
Common stock repurchases (in shares)			17,000,000
Common stock repurchases	(409)		$ (409)
Common stock retirements (in shares)		(17,000,000)	(17,000,000)
Common stock retirements	(418)	$ (2)	$ 418	(416)
Conversion of Cimarex redeemable preferred stock	3			3
Common stock cash dividends	(895)					(895)
Other comprehensive (loss) income	$ (2)				(2)
Ending balance (in shares) at Dec. 31, 2023		751,000,000
Ending balance (in shares) at Dec. 31, 2023	0		0
Balance at end of period at Dec. 31, 2023	$ 13,039	$ 75	$ 0	$ 7,587	$ 11	$ 5,366